CPRC
AMGN icon

Consolidated Portfolio Review Corp’s Amgen AMGN Stock Holding History

Consolidated Portfolio Review Corp’s Portfolio AMGN Stock Details AMGN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2025
Q4 		– Sell
-5,702
Closed -$1.61M – 50
2025
Q3 		$1.61M Sell
5,702
-109
-2% -$31.6K 0.2% 122
2025
Q2 		$1.62M Buy
5,811
+68
+1% +$19.3K 0.22% 107
2025
Q1 		$1.79M Buy
5,743
+1,077
+23% +$318K 0.29% 90
2024
Q4 		$1.22M Buy
+4,666
New +$1.38M 0.19% 124
2024
Q1 		– Sell
-923
Closed -$266K – 279
2023
Q4 		$266K Sell
923
-211
-19% -$57.5K 0.06% 249
2023
Q3 		$305K Buy
1,134
+86
+8% +$21.5K 0.07% 236
2023
Q2 		$233K Sell
1,048
-51
-5% -$11.8K 0.06% 278
2023
Q1 		$266K Buy
+1,099
New +$270K 0.07% 226

Other funds holding AMGN

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Capital World Investors
Capital World Investors Los Angeles, California $733B AUM 35.63% 1-Year Est. Return
Capital International Investors
Capital International Investors Los Angeles, California $427B AUM 29.17% 1-Year Est. Return
Invesco
Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Charles Schwab
Charles Schwab San Francisco, California $654B AUM 26.35% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Consolidated Portfolio Review Corp's AMGN Position: Q4 2025 in Review

Consolidated Portfolio Review Corp sold out of Amgen (AMGN) in Q4 2025, closing a stake of 5,702 shares — an estimated $1.61M sold.

Consolidated Portfolio Review Corp first reported a position in AMGN in Q1 2023 and held it in 8 quarters. The position peaked at $1.79M in Q1 2025. 3,086 funds tracked by Wall St. Rank hold AMGN as of Q4 2025.

  • Consolidated Portfolio Review Corp reported no remaining Amgen position as of Q4 2025 after selling out during the quarter.
  • Consolidated Portfolio Review Corp sold 5,702 Amgen shares in Q4 2025, an estimated $1.61M.
  • Consolidated Portfolio Review Corp first reported a position in Amgen in Q1 2023 and held it in 8 quarters.
  • Consolidated Portfolio Review Corp's Amgen position peaked at $1.79M in Q1 2025.
  • 3,086 funds tracked by Wall St. Rank held Amgen as of Q4 2025.

Based on Consolidated Portfolio Review Corp's 13F filing for Q4 2025, filed 26 Jan 2026.